Coronavirus company news summary – Moderna says its Covid-19 vaccine is effective in older adults – J&J to study Covid-19 vaccine in Latin America

27 August 2020 (Last Updated August 27th, 2020 09:10)

27 August 2020 

Moderna has reported that its Covid-19 vaccine candidate, mRNA-1273, induced immune responses in older adults in a Phase I clinical trial, indicating its potential for use across multiple age groups. The latest results are from an analysis of 20 additional older volunteers who were given an 100μg dose. According to the company, the immune response was similar across age groups of 56 to 70, above 70 and 18 to 55 years.

Celltrion Group has received approval from South Korea’s Ministry of Food and Drug Safety (MFDS) to conduct a Phase I clinical trial of the antiviral antibody treatment candidate, CT-P59, against Covid-19. The company has started enrolling patients with mild symptoms.

The collaboration between the National Research Council of Canada and China-based CanSino Biologics, announced in May for vaccine clinical trials, has been terminated after China had held up vaccine shipments, according to CBC news agency. As part of the alliance, the Canadian Centre for Vaccinology at Dalhousie University was supposed to be conducting the first human trials of CanSino’s Covid-19 vaccine candidate in the country.

Johnson & Johnson has plans to expand the Phase III trials of its potential Covid-19 vaccine candidate to Chile, Argentina and Peru, pending regulatory approvals. The trial is expected to enrol 60,000 participants across Brazil, Chile, Colombia, Peru, Argentina and Mexico.

Researchers at Fujita Health University in Japan have said at a news conference that their study found low concentrations of ozone could neutralise coronavirus particles. The research involved an ozone generator in a sealed chamber with a coronavirus sample. It was observed that ozone gas in concentrations of 0.05 to 0.1 parts per million (ppm) was able to reduce the virus’ potency by more than 90% after ten hours.